Results 211 to 220 of about 10,935,890 (352)

Antitumor Compounds From Halophilic Streptomyces violaceorubidus M4 Against Triple-Negative Breast Cancer. [PDF]

Microbiologyopen
Zia A, Salehghamari E, Jalali H, Taher M.   +3 more
europepmc   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Looking at Cancer [PDF]

CA: A Cancer Journal for Clinicians, 1963
openaire   +8 more sources

Disparities in cancer incidence, stage at diagnosis, treatment and mortality across socioeconomic groups in Finland: a register-based population study. [PDF]

BMJ Public Health
Zai X, Li P, Dei Bardi L, Korhonen K, Moretti M, Myrskylä M, Martikainen P.   +6 more
europepmc   +1 more source

A Study of the Distribution of Radioactive Phosphorus in Three Cases of Cancer [PDF]

, 1946
A. Forssberg
openalex   +1 more source

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

Science Signaling, 2013
Jianjiong Gao, B. A. Aksoy, U. Dogrusoz, Gideon Dresdner, Benjamin E. Gross, S. O. Sumer, Yichao Sun, A. Jacobsen, Rileen Sinha, E. Larsson, E. Cerami, C. Sander, N. Schultz   +12 more
semanticscholar   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Cancer In the Aged [PDF]

CA: A Cancer Journal for Clinicians, 1964
Henry Eisenberg, Sidney J. Cutler
openaire   +5 more sources

Growing burden of early-onset pancreatic cancer without increasing risk: what is the trick. [PDF]

NPJ Precis Oncol
Braggion A, Chiolero A.
europepmc   +1 more source

The Mortality from Cancer of the Skin and Lip in Certain Occupations [PDF]

, 1949
M Atkin, J Fenning, J. A. Heady, E. L. Kennaway, N. M. Kennaway   +4 more
openalex   +1 more source